Runat-bi: a ruthenium(iii) complex as a selective anti-tumor drug candidate against highly aggressive cancer cell lines

HIGHLIGHTS

• who: Marta Albanell-Fernu00e1ndez and colleagues from the INCLIVA Biomedical Research Institute, Hospital Clu00ednico Universitario Valencia, University of Valencia, Valencia, Spain have published the article: RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines, in the Journal: Cancers 2023, 69 of 19/Dec/2022
• what: Ruthenium-based antitumor agents such as Runat-BI are an interesting alternative to current chemotherapy agents, overcoming many disadvantages of the latter due to their specific_activity against different cancers, more favorable toxicity profile and multitargeted mechanism of action.
•  

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.